Is Zimmer Biomet Stock Underperforming the Nasdaq?

Is Zimmer Biomet Stock Underperforming the Nasdaq?

Wed, September 16, 2026 at 7:37 PM GMT+3 2 min read

• ZBH -2.61%
• ^IXIC +1.69%

With a market cap of $18.8 billion, Zimmer Biomet Holdings, Inc. (ZBH) is a global medical technology company specializing in musculoskeletal healthcare solutions. The company designs, manufactures, and markets products ranging from orthopedic reconstructive implants to sports medicine, spine, craniomaxillofacial, and thoracic solutions.

Companies worth more than $10 billion are generally labeled as "large-cap" stocks and Zimmer Biomet fits this criterion perfectly. Its innovations support surgeons and healthcare providers worldwide in treating disorders and injuries of bones, joints, and soft tissues.

More News from Barchart

Shares of the Warsaw, Indiana-based company have declined 8.4% from its 52-week high of $106.88. Over the past three months, its shares have returned 9.3%, outpacing the broader Nasdaq Composite's ($NASX) marginal drop during the same period.

ZBH stock has risen 8.6% on a YTD basis, lagging behind NASX's 12.6% increase. Moreover, shares of the medical device maker have dropped 1.5% over the past 52 weeks, compared to NASX's 17.2% return over the same time frame.

Yet, the stock has been trading above its 200-day moving average since late July.

Zimmer Biomet shares rose 2.5% on Aug. 5 after the company reported strong Q2 2026 results, with net sales increasing 4.8% to $2.18 billion and EPS jumping 33.8% to $1.03. Adjusted EPS was $2.07, operating cash flow reached $447.9 million, and free cash flow was $308.3 million, highlighting solid cash generation. The company also raised its full-year 2026 revenue and adjusted EPS guidance, supported by healthy underlying markets, progress in its commercial transformation, and continued momentum from its innovation pipeline.

In comparison, rival Penumbra, Inc. (PEN) has lagged behind ZBH stock on a YTD basis, with PEN stock rising 2.6%. However, PEN stock has increased 21.3% over the past 52 weeks, outpacing ZBH stock.

Due to the stock's underperformance over the past year, analysts remain cautious about its prospects. ZBH stock has a consensus rating of "Hold" from 29 analysts in coverage, and the mean price target of $105.58 represents a premium of 7.6% to current levels.

On the date of publication, Sohini Mondal did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com